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Type I interferons have been used to treat viral infcctions and canccrr howcvcr,
IFN treatment is not always effec t ive due to the presence ofcel lulars uppressors o f the
IFN pathway such as Ras signalling activation. We have investigated whether inhibition
01'Ras signalling at the level oft he MEK promotes the expression 01'IFN-inducible genes
i ll vivo, Bi\Ll 3/c mice were injected intrapcritoncally with either DMSO/I'BS. an
inhibitor I()(' MEK (SL327. 100 ru g/kg BW). IFN-u ( IOx IO~ U/mouse) or SL327/IFN-u
combined. At S hrs aftc r injection. the brain. intestine and lung were harvested for
confi rmation ofM liK inhibition and semi-quantitative expression analysis for thrcc IFN-
inducible genes: Chll ] . Rig-/a ndS IIII] , Western blot analysis ofp roteins isolated from
SL327 treated lung showed reduced levels ofp hosphorylated substrate. indicating that the
drug worked effe ct ive ly to inhibit MEK invivo , IFN significantly induced the expression
ofa ll genes in intestine and Rig-lin the brain; however. there was no signilicant induction
ofg ene expression following the SL327 treatment and no synergistic effec t was observed
following the co-injection 01'SL327 and IFN-It, The results oft his work suggest that
MEKi nhibitionc annote l'ICctively promotet ranscription ol' lFN-inducible genes under
physiological conditions i ll vivo,
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Chapter I: Introduction
/.//NT/:'RFDWNS
Interferons ( IF s) are cyt okinc s best recognized fix their pivotal role in ant iviral
defen ce in lllallllllals( I.2). IF s wcrc discovcred by Isaacs and l.indenlllann (1957)
while they were studying thc mcchan isms of' nmiv iral defence, and recognition of their
ahilityi n inrcrfcring with viral iniection ied lo their nolllinationas"i nlcr ierons" bythcsc
scientists (3). In contrast to antiviral drugs used at that time, llN s had almost no toxicity
and acted aga inst u widc range of viruses. These unique propertics madc them supcrior
over common antiv iral substances. which encouraged virologists to furthcr invcstigntc
and expa nd their knowledgeof lFNb iok 'gy( l.2 .cJ). IF s wcrc thc fi rst cytokincs
identified. purified. cloned. sequenced. and produced in rccombin ant Ionn for clinical use
(3.5 -7).
IF ls are a group of pleiotropic cyto k incs with antiviral. antitumor. and
inuuun omodulatory functions (1-3). Based on the range and importance o ft heir activitie s.
IFNs have been used lor the treatment of various pathologica l conditions. includ ing
certa in viral infection s, scvcral typcs o lcanccra nd uuroimm unc discnscs tx-l Zj. Thc
biological functions and subsequent iniervcntional properties ofl FNs arellled iatedbylh e
IFN stimulated genes (ISGs). which comprise a large group o f genes with great diversity
in Iunction tlnhlc 1.1) (13).Theyarecla isilied into three groups according to their
receplor spec ilici ly and alllinoac id sequcnce holllologyas type l. type lla lld type lll
IFNs (l cJ).
Tahlc 1.1 Gcnco ntologyc lassilica tions of lSGs
Fuuct ionn l Ca teuorics
Adhe sion
Anuioucncsis
Anti gen presentati on
Anti gen prece ssin g
Anti vira l
Ap optosis
Cancer
Cel l-cel l adhesion
Ccll cvcle
Chcmokinc
Cv toskc lcton
Dcvclop ncnt
DNA replication/repair
Extracellularma trix
Gvprotcin signal l ing
Growth factor
G'lP vbindinu
I lost dc I ~:usc
Immune modul ation
ln fl amm..ui on
Lvmnhocvte adhesion
On cogen e
Protea se
Protease inhibitor
RNA splicing
Transcription factor
~~tiona l ac t i v a tor
'I'ranscriptional rcprcssor
Translati on
Tum or sunnrcssor
Ubiquitination
Vesicle transport
Adapt cd trom rcf crcncc t l J)
1.1.2 Type l Intcrfcrons
Type II FNs are a multi-gene llullily comprised ol'eight subclasscs in manuua ls:
IFN-u,I FN-[l. IFN-E, IFN-". IFN-Ul. IF1\-T.I FN-o. and IFN-s cra ble 1.2) ( 15. 16). Each
gene iscn codcd by a singlc cxon on human chromosome (ChI')9. and mouse Chr4( 17).
The size of type II FNs ranges fro m 165-200 al11 ino aeids and their sequence homology
rangesl i·om 30-S0 %w ithin speeies (6. 15, 16). IFNsac tivate intraeellular signalling
networks in an autocrinc and paracrinc manner by binding to herero-dimcric ccll surfacc
receptors. IFN-u receptor (IFNR) I and IFNR2 . which arc distributed in all human cell
types ( I. IS, 19). Antiviral. immunomodulutory, and unt it umoractions nrc thc main
functi ons oft he type II FNs (I . 2).
In mammals. type I IFNs arc considered the principal antiviral cytokincs with
significant regulatory roles in innate and adaptive im111unc responses. To induce innate
immune responses. they act directly on uniu fcctcd orv irally inlcctcd cc l ls. xvh ich lcnds to
inhibition ofv iral nucleic acid replicntion and mlt Nzvtranslation (20). Type IIF Ns
accomplish this by signalling the up-regulation ol' lSGs that mcdiatc thc antiviral attack.
Examples ofantiviral ISGs arc: 2 ' 5 ' -O l i ~:oadeny la te synthetase (Oi\ S). dsRNi\ -activaled
protein kinase (I'KR) and Myxovirus resistance gene (Mxr. which plnyim portunt roles in
typc l llN vinduccd innate immunity (2). The antiviral activity oI'2'S' -Oi\S targets viral
RNi\ . while I'KR targets viral translation. and M:--: targets viral replication.
Tahlc 1.2 Expression pattern oft ype Il l' s in IIIaIII111aIs
Ex prcss lon pattcrn T\'(lCI IFNsllhtYllCS
u l, n2. u3.u4. u5. u6. a ] ,
Ubiquitouslyexpressed uS. ul O. u 13. u 14. u \6.
uI7.u2 J. 11
Leukocytes (J)
Uterus. Ovarv c
E iidcrmal kcratinocvt cs K
'I'm hob last , '.or
Snlccnthvmus. Jvmnh nodc Z
" Absent in mice: b Ruminants only: " Pigs und cuu lc only
Adaptcd li'olll referenccs( 15)a nd( 16)
2'S' -OAS activates a latent ribonuclease termed RNAasc L. leading to degradation 01'
host and viral RNA (2 1), I'KR inhibits viral translation through phosphorylation and
subsequent inactivation of cukaryotic initiation factor 2u (22), Mx blocks viral rcplication
viai nhibiliono l'viral translocalionac ros i thc nuclcar mcmbranc (23).
Type I IFN-induccd adaptivc immunity is mediated through their
immunomodulatoryl' unctionsa nd subscqucnt promotion ol'antigcnp rcscnlation and
pathogcn clcarancc stagcs( 24. 25).T ypc IIF Ns cnhancc thc proccss ol'antigcn
presentation through induction o fd i ffe rcntiarion oI'T-hclpcr( Th)- 1 cclls (26).
dilkrc nliation and activaliono l'dcndriticc clls (DC) and incrcascd cxprcssiono l'major
histocompatibility complex (Mi le) Class I and MIIC II (27. 28), Their promotional role
to stimulate the formation and activity ofc ytotoxic T lymphocytcs (29. 30).i nduction ol'
macrophagc (3 1) and natural killerc ells (NK) activity (32. 33) faci lita tes elimination 01'
virullyi nfcctcd cclls. NOlably. thcsc immllnoll1odulatory l'unctions highlight the
importance of type IIF Nst obridgc thc innatc and adaptivcimmunc rcsponscs.wh ich
cmphasizcs thcir quality asstrong anliviral cncctors.
Type II FNs inducc anlitumorrcsponscs throughdi rccta nd indirect eff ects on
tumor cell growth and progression. Dircctly. jhcy rcducc oucogcnc expression such as
Myclocytomatosis viralo ncogcnc homolog (c-Myc). and thcy inducc lumor supprcssor
gene expression such as the tumor nccros s facto r (TNF) receptor fam i ly and protein 53
(1'53)(4 .2 1). lndircctly. thc antitlimor clk ctso l'typc I IFNs arc mcdiatcd by increased
immllnc-mcdiatcd tumor survcillancca nd down-rcgulationo l'proangiogcnic molcculcs
(34. 35). Thc immunomodulatory l'unctionsol' lypc I IFNsa lsoca lisc stimulation ol'
adaptive illllllunityrcsponscsa gainsttul1lor cclls, which promote host imIII unc
recognition and eradication ofemerging turnorc c l ls. Tn addition, both IFN-u and IFN-I\
down-rcgulatc scvcral illlportant proangiJgcnic lllolcculcs sucha S lllatrix lllctalioprotcin
(MM I'9),vascular cndothclialgro wth filCtor.a nd basic fibroblast growth factort o restrict
blood vessel supply (36). Through their broad illlillunorcgulatory and antiangiogcnic
activitics. jypc I IFNs suppress tumor initiation and progrcssion.Thi si sthcbasis for
clinical research initiatives that incorporate type I IFNs into antitumor thcrupcutic
stratcgies (34).
1.2 TYPE I/FN I'!?OJ)UCT/ON PATIIW ,/YS
Inlll allllllalian organisllls,thefirsl stcpt o control viralinf cctioni sdcl cclion of
these pathogens, which subsequently triggers induction of innate immune responses. The
scnsing of' viruscs and subscqucnt induclion ofl ypc I IFNsi slll cdiatcd bytwo pathways:
the Rctinoic acid inducib le gene-I (RIC-I)-dcpcndcnt pathway and the Toll-like receptor
(T l .Rj- dcpcndcnt pathway (37, 38). These pathways show some cell specificity; lor
example. type I IFN production in macrophages and DC is mediated through TLR-
dependent pathways (39-4 1) and in other types ofc ells, including both immune and non-
immune, is stimulated by RlGvl-dcpcndcut palhway (39, 41-43). Several transcription
factors can be activated by RIG-I and TLR pathways through different mechanisms, but
thep roduction oft ypeII FNsi s stilllulatcdby activation of lntcrtCronrcgulatory factor
(IRF)3 and IRF7 (44, 45).
1.2.1 RICJ-I dependent pathway for IFN induction
RIG-I (DDX58) functions as a cytoplasmic sensor lor different types or RNA
viruses, including singled-stranded RNA (ssRNA) viruses harbour ing a 5'-Triphosphatc
(5'-1'1'1') group (46-48) and double-stranded RNA (dsRNA) viruses (49, 50). RICJ-I
belongs to DEAD (Asparaginc-Glutaminc-Alanine-l listaminclAsparaginc)-box RNA
hclicasc family (43). This family ofproteins usc nuclcotidc triphosphatc (NTI')s as source
ofenergy to mediate a varicty o f' func tions such as translation. transcription. mRNA
splicing and RNA decay (51. 52). RIG-I consists offo ur functional domains: two amino-
terminal caspasc recruitment domains (C.i\RD) (43. 53). a central DEAD-box hclicasc
domain (43. 54. 55) and aC -terminal domain (CTD) also known as the repressor domain
(RD) (50. 53. 56. 57). The CARD domains are responsible for transmitting the signal
from RIG-I ro downstrcam signalling mo lecules: the DEAD-box hclicasc domain is
responsible for both RNA recognition and providing energy for confonnatioual changcs
through the hydrolysis or ATI' : the CTD/ RD domain is responsible 1(11'both inhibition or
RICJ-I signalling and recognition or RNA viruses, RIG-I is inactivated in the absence or
viral RNA. and in this state the CARD domain is masked by CTD/RD domain to repress
signalling to downstream molecules (Figi rc 1. 1) (58). Viral binding to CTD/RD or
DEAD-box domains activates A 'l'Pasc activity leading to the unmasking orC ARD
domains and activation o r signalling (50. 59). The CARD domain or activated RICJ -I
interacts with the CARD domain ora mitochondrial antiviral signalling protein (MAVS)
also termcd IFN-[l promoter stimulator I l iPS- I) or VISA or CARDIF (25. 60).
Viral RNA
FigUl"C 1.1 I~IG-I dependent productiun of tYIICI IFNs. Binding o f virus to RIG-I
induces conformational changes and its subsequent activation. Activated RIG-I induces
activation of MAVS which in tum activates TBK I and IKKl: thro ugh phosphorylation
After phosphory lation by T BK I and IKKl:, IRF3 and IRF7 translocatc to the nucleus and
inducc transcriptionofTypc l lFNs
Activated IPS-I relays the signal to the TANK-binding kinase I (TI3K I) and inducible
Iid~ kinase (IKK-i: also known as IKKc). which phosphorylate IRF3 and IFR7 (6 1. 62).
Phosphcrylatcd IRF3 and IRF7 transioeate to thcnu elcust o aetivatctranseript ion o rt ype
I IFNs (44. 45).
1.2.2TLR-dcpcndcnt pathway lor IFN induction
TUb arc a nUllilyo r trans-mcmbranc protcins that scnscd iflc rcntt ypcsor
pathogens at the cel l surface or in the endosome (63-66). Among TLRs. TLR3. TLR7.
TLRXand TLR9 arc localized in the endosome and arc able to induce Type 1IFN
dependent antiviral responses (37. 67). The best known ligand 1'01'TLR3 is dsRNA. lor
TUn/X is ssRNA and for TLR9 is viral DNA or bacterial DNA with a CpG moti r( 6X-
75). In all TLRs. rccognition ofv iral particles is mediated by the leucine-rich-repeat
(LRR) domain. and they also posses the Toll-intcrlcukin I receptor (11.-1R) homology
(TIR) domain. which is a docking site for downstrcum adaptor proteins (Figure 1.2) (76-
79). The TIR-domain-containing adaptor-inducing IFN (TRIF) serves as an adaptor
protein lor TLR3 signalling. while Myelo id different iation primary response Gene XX
(MyXX)serves as an adaptor protein for TLR7. TLRXand TLR9 signalling (XO. XI).
These adaptor proteins activate TBKl ane IKKf; (X2. X3). which in turn phosphorylate
IRF3 and IRF7 (61. 62). Phosphorylatcd IRF3 and IRF7 subscqucntly translocatc to the
nucleus to activate transcription oftype I IFNs (44. 45).
Fig UH' 1.2 Til l' TL H.-dI' IIl'IIlII'Jll producti on oft ype I IFNs. Binding ofviral prod ucts
(ssR A. dsRNA. CpG) to the LRR domai n oft he TL Rs resulted in their activati on. Upon
activation. TLR3 activated its downstream adaptor protein T RIF while MyDXX is the
downstream targel of T LR7. TL RX. and TLR'J. Upon activation. TRIF and 1\1IDXX
activate TBK I. and IKKl: which phosphor, late IRF3 and IRF7. Following
phosphorylation. they translocate to the nucleus and induce transcription ofTyp e Il l' s
1.3 TYPE II FN SIGNAL/JNe; I'ATlIWAY
llN s scrvc to establish an antiviral state in the host organism II)Ilowing viral
infec tio n. Following their secretion from virally in fectcd cclls. H'Ns act in both an
autocrinc and paracrinc mannerto up-rcgulatc ISGsin both infe cted and non-infe cted
ncighboring cclls (84). A well recognized signaling pathway important forrcl ayo ft ypc I
lIO N actions is the Janus activated kinase-signal transduccr und activation oftra nscription
(Jak-STAT) pathway (2. 85-87). Members oft he janus famil y ott yrosinc kinascs t .luk)
and signal transduccr andactivator oftran scription (STAT) proreins arc the principal
componcnlsof .lak-STAT pathway thatc;I n bc induccd by scvcral cyrokincs bcsidcs lIO Ns.
Jak l (88) and Tyk-2 (89-9 1) oft he Jak fami ly. and STAT I (92. ( 3) and STAT2 (94-96)
oft hc S'I'A 'lfamilyplayccntrul roles in type I lIO N signaling (20).
Autocrinc orp aracrinc llN signaling is triggered bybin ding oft ype I lIO Ns to
thcir hctcro-dimcric cc ll surface receptors comprised ofo ne IFNRI and one IFNR2
subunit. lntraccllulurly. IFNRI is associated with Tyk-Z and IFNR2 is associated with
Jak l (97-99). such that lIO N binding stimlilatcstran sphosphorylationand subscqucnt
activationo f Tyk-2and .lak l. rcspcctivc1y( Figurc IJ)(98. 1(0). Activatcd Jak l and
Tyk2 phosphorylatc thcirassoci atcd rcccptorso n thcir tyrosinc rcsiducs in thc
cyloplasmic domain. l'hospholyrosyl rcsiducs acl as a dockingsitClo rccruit STAT2 (9().
1( 1) leading to STAT2 phosphorylation byJa k l and Tyk-L which accclcratc
phosphorylation of STAT I by these kinascs (2. 102). Once phosphorylated. STAT I and
STAT2 1IJr111 hctcrodimers, which in turn bind to IRF9 and IIJrl11 a trimcric complcx
termed IFN-stimu lalcd gcnc IllCtor 3 (ISGF3) (20. 1(3).
IFN St im ulat ed Ge nes
ISGs\
ISGF3 \
\
ISGF3
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Fignn ' 1.3 TYIll' II FN signalling pathway. Ty pe II FNs bind and activate IFNR I and
IFNR2 which in turn activate Tyk2 and Jak I, leading to phosphorylation of STAT2 and
STAT L Phosphorylated STAT2 :U1 d STI lT I form hctcrodimcrs which binds to IRF9 mill
forms a trimeric complex named ISGFJ . ISGFJ translocates to the nucleus and activates
transcription of IFN-induciblc genes
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ISCiF3 lransloca lcs to lhc nuclcusand binds lot hc lFN-stimulatcd rcsponscc lcmcnt
(ISRI:) in thc promotcrofISt.ls to inducetheir expression (2, 104) ,
1.-1. M UL7'lFUC7'lONAI, ISGS WI7'lII'fII07>1I.UOI,ES IN TJ'f'I~' I IF N SI( iN/ IU IN(i
IA.I CiBI'2
GBI'2 is one memb er of the CiBI' famil y, which arc one class o ft he type IIF N-
induced guanosine triphosphatase. Their naming as Gll l' is based on thcir capacityt o bind
ugarosc-immobilizcd guanine nuclcotidcs ( 105- 107). GBI'2 is a cytoplasmic protein that
was first ident ified li'om a cDNA libraryobtained from type l and type ll ll-N-trcatcd
human Iibrohlast cel ls in 1991 ( lOX). GBI'2 ' s high rate ofi nduction (> 6 fo ld) ((lilowing
exogenous type I and type IIIF N has led toits rccogllition as onc orth cmarkcrs orl FN
rcsponsivcncss t lO'i, 106, 109-1 12). There is ev idence lor both antiv ira l and antitumor
properties for GBI'2. The antiv iral activit ies or GBI'2 were first identified by Carter <,Iil l.
in 2005.Thcy showc dG Bl'2 has anlivira lac tivitya ga inst vcsicular stomatitisv irus
(VSV) and cnccphalomyocarditis virus (I:MCV) ( 109). GBI'2 1llcdiatcd its antivira l
activities aga inst VSV in a G'I'Pusc-dcpcndcnt manner and against I:MCV in a G'lP asc
independent lllanncr (109).lnadd ition,CiBI' 2was onc orth cup-rcgulatcd gcncs in lungs
ofp igs infected with l'orcinc Circovirust ypc 2 (113). Fernand es <,I il l. suggested the
antivira l ucriv uy ofG tsl' z agnmst this virus is mediated through T-cc !l act ivation, which
imp lies an immun omodulatory rolc and GBI'2 involv ement in adaptive immuni ty (1 13).
The antitumor funct ions or GB1'2, which were discovered in the context o ft ype II IFN
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signalling. arc also mediated through down regulation ofa n angiogenic 1;\ctor.1\11\11'9.
andd o\\'n rcgulationo raccll migration l;lctor. Rac (114.11 5).Ovcrall. cvidcnce suggests
a broad range ofactivities lor GBl'2 . pivotal for antiviral and antitumor responses
induced by IFNs.
104.2 RIG-I
In 1997. RIG-I \\'as idcnlilicda s oncorthe gcncslhatmediatcsa ll-transretinoic
acid-induccddilkrentiation oracutc promyclocytic lcukcmiace lls( 116). ln2004 .
Yo ncya ma cr o/, recognizcd antiviral properties orRI G-I ( 117). Thcyl i.JulHl that it
triggered production oft ype I IFNs through sensing or RNA viruses, lntcrcstinglv, its
express ion is also under regulation by IF -ls: therefore, RIG-I is catego rized as an ISG
\\'hichc nables RIG-l to rurther promotc innatc immuncrcsponscs ina positivc fecdhack
100p ( 117). RIG-I is u kcycomponcnt ofH 'N production. as many posi tive and negative
regula to rs ofthe 11'1 pat hwa yexert theire ffe cts at the level o ft his protein (39. l lS. 119).
RIG-I is ubiquitously expressed in most cell types and recognizes RNA viruses with
specific molecular features. including: 5'-1'1'1'. ssR A. dsRNA form s. This is
hypothesized to be a practical strategy Ior cclls to discrim inatc scl fR bl/v molecul es from
non-sclrR NAandthusprcv cnt autoimmllncrc actions (42. 54.5 S. l lS), More than
t\\'cnty RNA viruscsarckno\\'n lohcreccgnizcd by RIC-I. including so me that have
severe effects on human health. including: hcpatit is C virus( IICY). human
immunodcficicncyv irus (I IIY)and influenza virus tlab lc l .J) (39. 117. 120).
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Ta ble 1.3 RNA viruses sensed by RIG- I
Familv Viruses
Rhahdoviridae Rcoviridac, Rabies virus
Scndai virus, New Castle disease virus,
Paramyxo viridae Respiratorys yncytical virus,
Measles virus, Ninah virus
Orthotnvxoviridac lnflucnza Av irus. Influenza Il virus
Ebola virus, ll cpatitis C virus, Japanese
Filoviridae encephalitis virus, Dengue virus,
West Nile virus
Arcnaviridae LIssa virus
BIIII ) 'I / \' irit/lI l' Rift Valle ' feverv irus
Reoviridae Ort horcovirus
Adapted from reli:renees( 39),( 117),(1 20)
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Since the activation ofi nnate immunity is a crit ical step tor mounting long term adaptive
immunity. RIG- I can be considered an inj irect stimulalor o ra daptive immunity. ln
addition to this indirect influence. the inunun omodul atory funct ions or RIG-I on DC
( 121). 'I-cells (56). NK cells ( 122) and MIIC I expression ( 123). directly induce adaptive
immunity against viral ly infected cells and tumor cells. The anti tumor potential or RIG-1
was Iirst identified by Zhong Su ct 1/1. in W07( 124). They observed lower expression o r
this protein in severalc ancer models. including prostate. breast. melanoma and malignant
glioma cancer cell lines when coll1pared ton ormal cell l incs ofc quivalent tissue.T he
antitumor functions o r RIG-I arc mediated through apoptotic (122. 125- 127) and anti-
pro l i ferat ive ( 12X) activities. thus reduced expression or RIG-l lI'ould permit apoptosis
evasion and excessive pro li feration. C0ll11110n characteristics 0 t't umorcc ll s.
Overall. RIG-I has a significant impact on cellular signalling integration with a major
impact on host health. which has encour aged both virologists and cancer researchers to
focu s on this protein for the development o fi ntcrvcntiona l therapc utic approachcs t I v.
118.119. 127).
104 .3 STAn
STAT2 was fi rst identi fied by Fu " II/ I.. while they were exploring the polypeptide
composition or the lSGF3 complex in l9l)Othat was already recognized as a key
component of the IFN response( 129).S everal loss or runction studies demonstratedt he
potenti al or STAT2 as an essential compcnc nt ofty pe II FN signalling. Leung i'll/ I. round
that cclls lacking S'lA 'lZ havc dclcctivc typc I IFN rcsponsc (lJ5).Intll'o othcr
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independent studies, it was found thal SIII/2 knockout mice arc more vulnerable to many
typc s of' viruscs t l J fl, 13l ). Thcrc arct wo thcmcs ol"typc IIF N signallingp athway. in
both ol"whichSTAT2 is a key transcription factor: I) the classic pathway. described at
section 1.3. includes STAT2. STAT I andl k l'): 2) the non-classic pathway includes
STAT2 and othe r transcr iption facto rs rathe r than STAT I and IRF9. Int crms o ft he
classics ignaling palhway. thcrc arc two k atllrcs alrcady dclincd: l j rcquircd lcvcl of
STAT2 phosphorylation or threshold that is required for phosphorylation ol"STAT I and
subsequent form ation ofactive ISGF3 (102); 2) requirement ol"STAT2 for intcracting
with additional transcriptionbctorsa nd rcgulators o l"typc I IFNs igna lling ( 132-134).
There arc some type I IFN-induccd non-classic .lak-STAT signalling pathways. lor which
STAT2 is a pivotal transcription factor: I ) STATZ mediates signalling in a STAT I-
independe nt manncr through an active STAT2: IRF9 complex ( 135- 137); 2) STAT2
medi ate s signalling in an IRF9-indcpclltk nt manncr through a STAT2:STATI complex
(138); 3) STAT2 mediates signalling in a STAT I/IRF9 independent manncr
(STAT2:STAT3 complex, STAT2:STATS complex) ( 110. 139). All above examples
suggcst the dependency oft ype II FN signalling function to STAT2 rather than to STAT I
and IRF9.
Like RIG-I. Van et al. ( 1995) found that STAT2 is also an ISG. and thereby
amplifies type IIF N rcsponscs(9 I). STAT2 isc sscntial for ndaptivc immun ity against
viral and tumor cells o fm acro phage (3 1). DC( 140).an d Th cclls (14I).T hc lirsl
obscrvation o l"antitumor activity ol"STAT2 comcs trom a study in 2003. which showed
S/a/2 knockout mice deve loped brain tumors (142) . In addition. loss ol"STAT2
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accompanied tumor progression characteristic in co lorcctal. renal, and melanoma cancer
cells ( 143. 144). STAT2 also plays critical roles for inducing apoptosis of tumor cells
( 1-1-1- 1-16). inhibition ofc ell growth (140. 147) and down-regula tion of an angiogenic
fllctorivlM I'9(14li).Ol'crall.byitsdc tcrminantro lc in typc II I' signalling and
modulating vital biologica l process. STAT2 can be considered one oft he most prominent
ISGs. important lo r lidclityo f typc II I' signalling and hculth.
/ .5. /FN T/ /I:'RA/')' , IND tts /J ill/TAT/ ONS
1.5.I IFNt hcrapy
Based on their pivotal physiological roles. JlN s. especiallytype Il l' s. have
achieved a notable role in clinical medicine following thcir rccombinaut production in
19liO(I . 2).Thcir lirstcntry inc linics occurrcd in 19li51lJr trcatmcnt ofh airy ccil
Icukcmia(l ICL). 2li years after their discovery (1-19). Since thenthey have been
approvcdas a trcatmcnt fl)fv iral infcctions.c anccr. and multiplc sclerosis( i'vIS) as an
autoimm uncdi scasc (20.149).
Ofvira l discascs.f ype II I' s wcrc approvcd for trcutmcnt ofl ll jV t l Ju ).
IICY(15 1). herpes simplex virus (HSY) (152). lil Y ( 153.1 54). herpes zoster (155). and
common cold viruscs( 156. 157). but now they arc applied just Iorrrc uuucut ofl lll v and
IICY. IIBY is a serious intcrnational public health problem, with upproximatclv 400
miliionpco plc infcctcd lhroughout thc \\'cr ld( 15li). This inlCclionc auscss cvcrc
symptoms including liver cirrhosis and hcpatoccllulur curcinoma, thereby leading to
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chronic and deadly diseaseoutcollles ( 159- 16 1). IFN-u was introducedas the fi rst
intervention for I IBY in 1991 (162).lnlhe past twodecades.IFN-uhas been recognized
as an effective treatment . as it causes a reduction in disease severity in about 25-40'X,o f
patients (163. 1(4 ). IICY currently infe cts 175lllilli onpeop lew orld-wid e and induces the
same symptoms and outco mes as IIBY ( 165). The treatment of chronic IICY with IFNs
began with sole applicat ion of IFN-u. to which 20% of patients rcsponded ( 166).Co-
ndminisuution otllNvuj with lowdose (lflh e antiviraldru gribavirinl edto a synergistic
encc la ndi ncreased response rates to4 0%of patients ( 167).C urrent f(lI'Illo f treatlllents
includes application o f long-acting. pegylated IFN-u2with ribavirin which has led to
improvelllents-over 60% of patients are cured ( 168). l'egylated IFN-u2 consists of
polyethylene glyco l added to the IFN-u2. a chelllicallll odilicationwhich increases
IFN-u2 halllife and durati on of activit y (169).
Ty pe I IFNsare an illlportant treallllento ption l()r MS.which is ana utoimmune
disease. In this disease. neural transmission in the central nerv ous system (CNS) becollles
aberranta sa result of demyelination o fC NS. This is a consequence ofauto immune
reactions aga inst myelin ( 170- 172). Mx puticnts xuffcr from musc lc wcukncssm usclc
spasms or dif'ficulty in llloving. dif'ficuitics with coordination and balancc and visual
prob lems ( 173. 174).IF N-[l isthelll ain illlmunolllodu lalorym edicationl()rthi sd isease.
and its clinica l benefits are observed in 50-75'Yo patient s ( 175). It reduces CNS
inflammation. and thereby reduces symptoms o fp hysicul disabil ity(1 76).Th elll olecular
mechanisms through which IFN-[l exerls ilSciinical benefil saren olweliunderslood.ll is
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hypothesisedt hatt hosee lkc tsa rc mcdiatedt hroughi mmunomodulatorytilllction
of IFN-[1( 176).
Even though type I IFNs arc best recognized tor their unique antiviral propert ies,
they first entered into the clinic as an antitumor therapeutic agent lo r IICL in 19R5 (177).
Further investigations revealed their antitumor activ ity against somc othcr typcs of
cancer, which ultimalely lcd to lheir application l'or trealmento I'chronic myelo id
leukemia (CML), 13- and T-ce ll Lymphomas, melanoma, renal cell carcinoma (RCL) and
Kaposi' s sarcoma ( 149). Although fix some cancers such as CML and l fC L. type I IFNs
arc delegating their place to some new anticancer drugs, they arc still wide ly used 1'01'
treatment ofso me malignancies such as melanoma (34). Since 1995, IFN-u has been used
as an adjuvant therapy for patients with high risk melanoma (17R, 179). It benefits these
palientswithincreasedd isease- li'ee survival llx about9months, and overall survival by
R-9% ( IRO, IRI).
1.5.2 l.imitations ofI lN therapy
Type l llN s havc shown promise for the trcauncnt for some l i fe threaten ing and
debilitating diseases; however, their overall therapeutic effieacy is on ly moderate ( I. 2).
Onc obstaclc to thc succcss ofllN therapy is the phenomenon ofpat icnt resistance to IFN
treatment. Give n the potential ol' lFN therapy. understandingt hc obstaclcs to succcss of
IFN therapy might improve therapeutic outcomes, Three facto rs arc associated with IFN
resistance: I) genetic alterations ofc omponents involved in lFN production or IFN
signalling pathways ( IR2- IR4); 2)a nti-IFN proteins encoded by viral gcnomcs ( IR5.
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186): and 3) elevatedactivities o r endogcnous cellular suppressors or lFN signalling
(187- 190).
Mutations or polymorphisms or lFN signalingc omponents can changclFN
susccptibility li'om responsive to non-responsive phenotype. Forcxumplc. xlcfcctivc
STAT I expression correlates with IFN-(l resistance in CML and a cutaneous T-ccll
lymphoma ccli linc( 183. 184). In addition. Shang i'11I1. lcllll1d thata bolished Jak l.Tyk2
and Stat l cxpressionlca ds to impairment or Jak-STAT signalling. which underlies lFN
rcsistancc in RCL celi lines ( 182). Recognition o fi mpacts or mutations o f dilfcrcnt type I
IFN signalling will open an avenue ford evelop ing markers for future personalized
therapy decisions.
Viruses have developed strategies to shut down lFN signalling in order to evade
innate immune responses and support viral propagation. Viruses may counteract
IFN-mediated antiviral defences in either a direct or indirect manner (185. 187). Directly.
viruses encode proteins which disrupt the IFN signalling pathway through targeting its
components. For instance. Dengue virus encodes a protein which bindst oSTAT2 1eading
to its ubiquit ination and subsequent dcgradution t lv l ). A nothere xamp le is suppression or
RIG-I signalling by IICV; this virus encodes a protease which cleaves IPS-I (rom
mitochondria ( 192). Indirectly. viruses exploit cellular suppressors o fl lN signalling to
attenuate IFN response (193. 1( 4). Viruscs lacking anti-H'N proteins propagate
se lective ly in cells with elevated activity o ft hese cellular inhibitors.t hercby causingm ore
severe diseases in humans and animals ( I'J5- 197).T he up-rcgu lat io n ofcndogcnous
supprcss ors ofllN signalling was also observed in cancercells resistant to IFN (189.
2 1
190). This ev idence suggested these are serious barriers to lIO N therapy e fficacy and the
suppressor mechan isms have been the locus 01" recent researc h.
1.6. CEUULA R S UPI'R/:'SSORS OF IFN SIGNAUJNCi
The primary funct ion ofendogenous ce llular suppressors ol"lFN signalling is to
maintain thc homcostasis ofI l-N signal transduction ( 187). as prolonged or constitutive
activation ofI lN s leads to destructive biological conscquenccs such as ustlnua. futiguc.
and depression ( 198. 1(9 ). Threemajor l:ullilies o l"lype Il IO N signalling pathway
inhibilorsi nclude:S rc-homology2(S II2;'-containing phosphatases(S III'). lhe
supprcssors o fc ytokinc signalling (SOCS) family and protein inhibit oro fa ct ivatcd S'lA'!
(I' IAS) (Figure 1.4) ( 187). Activation 01" l ~ as/R al i'M EK pathway also was recognized as
inhibitoro fl l-N signalling in our laboralory (I 97).
PTP
PTP
PTP
Transcription
Figure 1.4 Suppressors of IFN signalling. The sacs family memb ers suppress Jak
kinases act ivity , or act as a competi tor of IFN in binding to receptors. PTP family
members de-phosphorylate Jaks and STAT I to induce ubiqu itin-media ted degradation of
Jaks. PIAS fam ily memb ers prevent tran scriptional activ ity of STA T dimer s.
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Phosphorylation is an integral feature oft he activated Jak-STAT signalling
cascade. such that de-phosphorylating events offer the cell a significaut lcvcl ofco ntrol.
SIIPI and SI1P2 are tyrosine phosphatascs involved in the negative regulation ofty pe I
lIO N signalling (200) . SIIPI attenuates type I lIO N signaling through de-phosphorylation o r
JaKI (20 1.202 ). whileS IIP2 inducesthe same suppression lhroughd e-phosphorylation
or STAT I (202.203) . Sodium stibogluconatc is an inhibitor of' both Sl l!' ! andS IIP2a nd
its combination with IFN-u showed significant synergistic cllc ct on IFN-u responsiveness
in both i ll vitro and i ll I"i\"() experiments (:~ 04 . 2(5) . This combination entered into phase I
trials forc valuutin g safety and target inhibition for treatment or melanoma (206).
The s acs famil y is comprised ofe ight members. including: cyto k inc inducible
SI 12containing protein and sacs 1-7 (207). Generally. their inhibitory eff ects are
mediated via three mechanisms: as antagonists for STAT binding to phosphorylation
target sites on receptors. inducers ofp rotcoso mal degradation o fb ound signalling proteins
and suppressors o lJ ak activity through a .i ind ing interaction (20S). Among the SOCS
famil y, sacs I and SaCS3 are involved in the negative regulation oft ype I IF
signalling (209). Up-rcgularion ofS tX' Sd is one oft he strategies used by lntlucnza A
virus and IIiV to suppress type I IF signalling (2 10. 2 1I ). The same mechanism is used
by IISV. as it induces sacs I or saCS3 tor evading llN vinduccd immunity ( 193. 212).
In addition. over expression orS aCS3 was observed in myelogenous leukemia cells
resistant to IFN-u ( IS9). The levels o fbo th sacs I and SOCS3 activity are determinant
l:tctors orIFN-susceptibilityi n melanoma (2 13). Furthermore. the level ofS OCS I and
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SOCS3 activi ty influence the interfero n r,:sponsiveness o rn euroendocrine tumor cells.
and RCLcelis. respectively ( 190. 2 14).
The I'IAS family includes I'IAS I. I'IAS2. I'IASx and I'IASy (2 15). I'II\ S I and
I' IASy are involved in negat ive regu lat ion o r type I lION signalling (2 16) . Both I'IAS I and
I'IASy bind to STAT I and disrupt its [) 'A binding capability (2 17. 2 1S). II was observed
that over expression o r l' lASy in mouse embryonic fibroblasts il/ l'itro diminished the
antiviral activ ity or lFN-u and lIO N-II against VSV. EMCCiV. and scnda i virus (2 19).
1. 6.1 Ras signaling
1.6. 1.1 The Biology ofRa s
The rat sarcoma virus oncogene (Ras) superfamily comprises proteins that share a
protein structure that binds to GT I' and possesses G'l'Pasc activi ty (220). They switch
between two states. an active (GTI' boun ). and inact ive (GDI' bound ) form (22 1). Th is
transition is controlled by intrinsic GT l'ase activity or Ras. guanine nucleot ide exchange
factor (GE F)s and G'IP asc activating protein (GAI')s (222.223). Ras proteins have low
intrinsic G'lPa sc activity. such that GE l's and GAl's act in a supplementary manner to
increase the rate o I'exchange and hydrolysis. respectively. CiI:Fs facilitate Ras activation
by promot ing the release or GDI' and exchange for activating GT I'. while GA l's Iacil i tatc
RAS deactivati on by promoting GTI' hydrolysis to GDI' (222. 223). The balance between
activation and deact ivation is very import .uu fornonna l tuncri on s of' Ras (224-226).
When activated int he GTI'-bound conformation, Ras interacts with many effectors to
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control numerous biological responses. including: prolifcratiou.ditfcrcmiarioucc!l
adhesion. apoptosis, actin cytoskclctul imcgrityand ccll migration (220). Characterized
Ras effectors are phosphatidylinositol 3-kinase. Ra I guanine nucleotide exchange factors
and the Serine /Thre onine prote in kinase l{ar (227. 22S).
1.6.1.2 Ras/Rati'MEK pathway
The Ras/Raf/Ml i}, pathway includes a cascade o r phosphorylation eve nts
perfor med by members o r three key k inase (ami lies: seri ne/ threonine protein kinase Ral:
mitogen-activated protein/cx tracellular s ignal-regulated kinase (MI:K). and Extra cellular
Signal-Regulated Kinase (ERK). This pathway can be activated in two ways. one is
regulated or physiologica l activa tion and the other type is constitu tive or oncogenic
activation (220).
Physiological activation o r the Ras pathways occu rs upon activation ofr eceptor
tyrosine kinascs (RT K) by growth factors and mitogens (Figure 1.5) (225. 226) .
Appropriate ligand binding is required to activate the RTK. which stimulmcs the
activation o fRas by inducing the GT I'-bcund state (226). Rafkinasc is recruited to the
plasma membrane by activa ted Ras. which leads to phosphorylation and activati on ol' Raf
(229). Phosphorylation cascades ensue. whcrc phosphorylutcd Rafphosp hory latc s MEl' .
which phosphorylatcs and activates ERK (230 -232). Activated ERK has a wide variety o r
targets in the cytoplasm and nucleus including kinascs. phosphatascs. transcript ion factors
and cytoskclctul protcins.
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Figure 1.5 Overview of physiological aetivation of the Ras/RaflMEK pathway.
Followi ng mitogen binding , a phosphory latio n casca de starts . Thi s ultimately leads to
stimulation of proliferation , growth, different iation or migration.
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The final outcome or physiological activr.tcd Ras/Ral/MlK pathway is induction o r
prolife ratio n. growth. diff erentiation and migration (233).
Constitutive activation oft he Ras/Raf/M l.K pathway leads to tumor development .
and aberrant activity of this pathway is almost round in one third ofa ll human cancers
(224) . This typ e ofac tivation is a consequence or activating mutation s in the early
components of this pathway including RTKs. Ras, or Ral: or amplification and
dcrcgulation or its downstrcamcflcctors (220). Thc outcomc is signallingpathway
activation that is autonomous from the presence or ligand. and overal l loss ofrcgulutory
control. The most abundant mutations involved in constitutivcactivation ofRas arc
mutationsa tami noacidrcsiduc 12. whiclJrcprcsscs GAI'-mcdiatcd inactivation of' Ras
(234. 235). and mutations in res idues 13and6 1 which result in rcpre ssion o tt hc intrinsic
G'lP ase activity or Ras (234. 235). For pathway components downstream or Ras. B-Rar
mu tat ions have been found in many type s or malignanc ics incIuding malignant
melanomas, co lon cancer, papillary thyroid cancers and serous ovarian cancer (173).
Overall, mutations responsible for over-activity ofRa s signalling pathwa yc omponents
have been found in 20-25% or all human tumors and up to 90% in spcci tic tumor typcs
such as colorcctal canccr (226): thcrcli.)rc. thcsc protcins havc bccn thc li.lcus or
chemo the rapeutic drugs lor cancer (236). One o ft he common Ras/RaI/MI:K pathway
inhibitors arc MEK inhibitors. because MEK is an important regu lation stcp lor the
pathway (237). Thcir potcntial thcrapcuti: bcnclits havc Icd to deve lopi ng diff erent types
or MI:K inhibitors with dilk rcnt strUclur.ll and chcmical propcrtics. in a way that thcy
target different MI:Ks with differe nt efficiencies (238). Two wide ly used expe riment al
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inhibitors o r MEK I and MEK2 arc UO126 and SL327. UO126 is used broad ly for ill vitru
studies and SL327 1i.Jrill vivo studies (239-24 1). The obstacles such as not being
suniciently soluble ors uniciently bioav,tilable and inability o r passing blood-brain
barriers restricted the i ll I'i\'lla pplication orUO l26 (236). resul ting in broad application or
SL327 i ll vivo, especially lor behavioral stud ies (240-243). Sc hc rlc 1'1al. applied both
UOl26 and SL327 in their in vivo studies. and ide ntifi ed supcriority ofS l.Ll ? over UOl26
lort he inhibition ofMl. K (244).
1.6. 1.3 Manipulation ofnor mal Ras/Ral/Ml -K pathway activity during viral infections
Many viruses evade the host defense system by activating the Ras/Raf/M lK
pathway. which is mediated through direct binding or the virus to its receptor or
interactionorviral proteins withc ellular signalling components.Forexa mple. lhe
coxsackie virus induces a biphasic activation or the Ras/Rali'MEK pathway to enhance its
protein synthesis and progeny production (244.245). UOl26 treauncnt oft hc infcctcd
cel ls significantly decreased viral produc. ion and protcin synthcsis (244. 245) . In the early
phasc ofb orna virus inf ecti on. Ras/Rali'i\lEK pathwa y activation facil itates viral
propagation. but UOl26 treatment reduces the spread oft his virus up to 99'Yo(23X). Rapid
transient activation o ft he Ras/RaIi'MEK pathway also occurs upon respiratory syncytial
virus (RSY) infection. Early activation o lt his pathway plays an important role in RSY-
induced early gene expression. since treatment with MEK inhibitorl'D9X059resuiled in a
signi fi cant reduct ion in the RSY inlection (246). l-urth crm orc visna virus inf ecti on
resulted in activation or Ras/Rali'MEK pathway in the early phase ofi nfection, and this
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activation rcmaincd during all phascso r inlection. Sincc l' D98059 treatment resulted ina
signilicant reduction ofrc plic.uion. it could bc concludcd that activation or Ras/Ral/Ml.K
pathway is ncccssary lC:Jrvisnavi rus rcplication (247). !\ s wcll. activationo r
Ras/Ratil'v1 EK pathway has been observed for many other viruses such as IIIV-1.
cyromcgalovlnrasimian virus. intlucnza virus. IIBV. IICV.andvacina virus (245. 246).
Collcctivcly. thcsc rcports dcmonstratc thats cvcral viruscs usc transient activation o r
Ras/Ra t/l'v1E K path wayas a tactic to evade innatc immun e responses.
1.6.1.4 Exploiting or constitutive Ras/Raf/MlK pathway lor promoting oncolytic viruses
infec ti on
l'v1any oncolytic viruses preferably replicate in canccr cclls harboring constitut ivc
activation or Ras/Ratil'v1 EK pathw uy to cvadc innate immune responses and spread thei r
progeny. l.xamp lcs oft hosc oncolytic viruses arc: reovirus (248). adenovirus (249).
polivirus (250). IISV (251). VSV (252). .md inf lu enza virus (de INS I strain) (224).
Constitutive Ras/Ratil'v1 EK pathway facilitates viral oncolysis generally through
promotingthreev iral steps.including:u ucoating orv irus (253. 254).lranslation orviral
proteins (242) and release ofne w progeny (254. 255).
1.6.1.5 A ntagonistic cross talk or the Ras/Ratil'v1 EK pathwayand Interferon pathways
Ample evidence shows that manipulation of Ras/Ralil'v1l :K signalling. either in
physiol ogical or in constitutive states. is a universal tactic by which different lyr es of
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viruscssupport thciro wn propagation.Our laboratory prcviously rcportcd thatt hc
Ras/Rali'MEK pathwa y is a cellular suppressor oft he type I IFN-induccd antiviral
rcsponsc (197).lnthis study. it was shown that IFN sensiti ve viruses can in fect NII13T3
ce lls with activated Ras (Ras v 12) in the presence or IFN-u. where as contro l cells with
normal Ras activity were protected from infection by IFN-u. MEK inhibition by chemical
inhibitors and knockdown o fR us by RN,\ interference (RNAi ) resto red IFN sensitivity in
thc Ras activatcd ce l!s. As external validat ion. Noserr/a!. 1(IUndthat IFN-induccd
antivira l responses were restored in human cancer ce ll lines following Ras/Ruf/Ml .K
pathway inhibiti on (256) . The ev idence puts forward two key points: I) that viruses
benefit from activated Ras signalling to r.void IFN-stimul atcd iuunuuc supprcssiounnd
2) that reversa l o fRas activation could scnsitizc cciis to thc IFN resp on se ,
Experimental effo rt s to identif y IFN signalling components targeted by thc Ras/Rali'MEK
pathway. revea led redu ced total STAT2 protcincx prcssiona nd rcduccd phosphorylat ion
or STAT2 and STAT I in RasVI 2 ce lls (:~57 ). UOl26 restored the IFN respon se
com plete lybut re-cx prc ss ion ofS' lA 'I? in RasVI 2 ccllsrcsultcd in part ial recoveryo f
IFN-induccd antivira l rcsponscs (257). I\lth ough STAT2 is rccognizcd as a Ras
/Rafi'MEK pathways target. evidence such as effec tive antiviral responses by IFN
treatm ent foll ow ed by MEK inhibition. and partial recov ery or IFN responses fo l low ing
over expression orSTAT2 suggested that Ras/Rali'MEK pathway targcts multiple
componcnts ofllN signalling. not ju st STAT2. Thcrcl(lrc. furth er experiments were
pCrl(lI'Illcd to dctcrmincothcr c!cmcntsor thc IFN signalling targeted bythe
Ras/Ra f/ Ml.K pathwa y. Global gene expression profilin g by microarray analysis was
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conducted to ident ify the ll -Nvinduciblc genes targeted by the Ras/Ral i'MEK pathway
(Christian. unpubl ished). NII13T3 cells transformed with constitutively active Ras (Ras
V 12) were treated with DMSO (control) IFN-u or UO126. RNA was extracted 6 hrs pOSI
treatme nt and subjected to mi croarra yanalysi s. Of 41960 gene iso forms represented on
the array. 1883 were up-regulated in the Ras VI 2 celistreated with UOl26 compared to
contro l, with a threshold criteria set loa > 2.5 fold increase. while IFN trc.um cnt alone
induced 1877 genes. Of these candidate genes. 6 19 were found 10 be up-regulated byboth
UOf26 and IFN treatment and the group was named MEK-down regulated IFN-inducib le
genes (MDII genes). Some oft he genes were known to have antiv iral fun cti on s. such as
Cih/)2. Rig-I , and S11I12. Accordin g to microarray analysis data. the UOl26 1reatmenl
resulted in 9.38 1()ld increase 1()r Cih/)2. 2.55 f()rR (l!,-I. and 6.4 1 f()r SI1I12 crab le 1.4). To
confinn microarrayan alysis. the same RNA samples were subjected to quantitative-
polymerase chain reaction (q-PCR) I(Jr Gbp], Rig-I , and S11I12. The results from q-PCR
analysis showed that MEK inhibition induced the expression of these tested ge nes
significantly and co-treatment ofUO I26/ IFN-u induced synergistic eff ects (Ta ble 1.4)
(Christian: unpubl ished).
Furtherexperiments wereco nducled toi nvestigate lhei nfluenceo f the
Ras/Rafi'MEK pathway on IFN resp on s ivene ss in human cancer ce ll lines. as many
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Ta ble I. .t MDII genes expression in Ra~;vI 2 cells following IF treatment. i\IEK
inhibition or the combined treatment in vitro
G ENE UU126 I FN UUI 26/ IFN
MieruarruvA na lvsis
(RasV I 2 Ce lls)
GhJ] 9.83 97.52 Ni\
Ril!,-/ 2.55 25A 6 Ni\
su»: 6.4 1 16.77 Ni\
q -I' CR An al vs is
(R a SVI 2 C ells )
Gh/J] 5.8 1 78 . 16 2 18.5 1
Rig- / 2.78 20. 10 24.64
SIal ] 3.7 4 10.6 1 24.25
oncolytic viruses exploit pathological activi ty o f this pathwa ya s a mean to replicate in
cancer cells (Christian ct. a l: unpublishec). Sixtccn ccll lincs ofdi lfcrcnt origin (3 breast,
I cervical. 4 colon. I fibrosarcoma. 2 melanoma. 3 ovarian and 2 prostate cell lines) were
tested for their sensitivity to IFN-Cltreatment . Three of them were IFN sensitive. 9 0f
thcm modcratclyrcsistan t. und-l of them were completelyres istant. Treatment of UOl26
improved the IFN responsiveness in IOout o fl 3 moderalely and compietely resistant ceil
lines. Further steps were taken to explore the mechanisms which undcrlie Ras/Raf/M l.K
pathwaymediated IFN resistance in thcsc cxamincd cunccr cc ll lines. Global gene
expression pro fi l ing by microarray analysis was performed on one IFN sensitive and one
moderate ly IFN resistant cell line treated with DMSO (contro l). IFN-l( or UO126. RNA
was extracted6 hrsand l2 hrs post trealrnenta nd subjectedtomicroa rraya nalysis.
UOl26 treatmenl increased expression ofa group of lSGs such as Gh112. Rig-l.and S/aI 2.
and these resu lts were confirmed byq -Pt .R analysis.
Followin g the observations that the cellular activity of the R/\ S/Rall ·IEK
pathwa y imposed a negative influence on cellular susceptibility to IF -induccd antiviral
and antitum or effects via a global down regulation of ISGs ill vitro , the next step was to
assess the physiologica l app lication o f these lindings in an anima l model. To our
knowlcdgc.jhis is thc li rst sllldyt estingl he erticaey o f MEK inhibition to promote IFN' s
transeripti onactivi ly illl'il'll . lli s the ullimate goa lo f thei nveSligationtoexp lore
intcrvc ntional stratcg ics that improvc thc cfficucyo fllN to cure diseases such as viral
infccrion. Mx and canccr.
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I .7. IIYI'0 7'l1l~SIS AND OB.fEC7JVES
1.7. l l lypothcsis
MEK inhibition will independently promote the expression of MD11genes, and
the co-administration of lFN and a MEK inhibitor will have synergistic effect on MDII
gcnc cxprcssion undcr physiologicalco nditions ill l'il'O.
1.7.2 0bjc ctivcs
I. Invcstigatcwhcthcrtrcatmcnt '.Vith aM EK inhibitor promotes expression of
rcprcscntativcM Dll gcncs(Ghp2. Rig-l. '11(112) in a mouse model.
2. lnvcstigatc whcthcrco -trcatmcl1\with a MEK inhibitor and IFN-uin duccs a
synergistic eff ect in the induction of MDII genes (Cihp2. Rig-I, SIil I2 ) in a mouse model.
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Chapter 2: Material and Met hods
2.1 MICE
Nine week old female mice of the Halb/c inbred strain (Charles River l.abs,
Boston MA) were used lix in vivoex periments.Twenty mieewered ivided into four
groups of five miee receiving the lilllowil1g treatments intraperitoneally (IP): control mice
received 80 ul of Dimethylsulfoxide (Dt'vISO) (Sigma. St. Louis MO) plus 1:20rLi
Phosphate Buffered Safine( PBS) (80 g sodium chloride.:2 g potassium chloride. 11.59 g
disodium hydrogen phosphate.:2g/l monIJpotassium dihydrogenp hosphate(Si gma.Sl.
Louis MO)) ; one group received 100 mg/kg BW orSU27 (Ascent Scientific. Cambridge
MA)d issolvedi n80rt!o f DMSO and then dilutedatl 20 pi: another group received
1000 U IFN-u (Pestka Biomedical Laboratories Interferon Sourcc. Piscataway Nl )
dissolved in 100 ul PBS . and one group was co-injected with SU27 ( 100 mg/kg) and
1000 U IFN-u in their respective vehicles. The mice were sacrificed 8 hrs after injection.
The brain. intestine and lungs were harvested to obtain protein samples forwe stern blot
analysis and RNA samples fix semi-quantitative PCk-bascd gene expression analysis.
2.2 1V1:'STERN IJUJTANA Ll'S IS
:2.:2.1 Preparation of protein samples
l' issucs were cut into about 50 mg pieces and homogenized in I ml of
radioimmuno precipitation assay (RIPA) lysis buffcrt lX PBS pI17.4 . I'X,n onidet 1'-40
(Sigma. St. Louis MO). 0.5% sodium deoxycholate (Sigma. St. Louis MO). and 0.2";(,
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sodium dodccyl sulphate (SDS) (USB. Cleveland 0 11)containing protease and
phosphataseinhibitors(IOOng/mlphenylmeth yl sulfonylll ouride (Sigma-Aldrich.
St. Louis MO). 2 flg/ml leupcpt in (Si gmr., St. Louis MO). 30 ug/m l aprotinin (Sigma. St.
Louis MO). 100 mM sodium vanadate (Sigma. St. Louis MO). and 500 mM sodium
lluoride( Sigma. St. Louis MO)).The lysate was centrifuged at 12000 xgl (lr l tl min at -l
°c. Supernatants conlaining cellular prott:ins were then separated li'om debris and kept al
-40 °C until the time of assay.
2.2.2 Quantification of protein
The amount of protein was measured with bicinchoninic acid (BCA) Protein assay
kit (Pierce Biotechnology Inc.. Rockford. IL). BCA reagent (50: I. reagent A: reagent B)
was added t05 0 ftlof protein sampleso r standards prepared lrom bovinc serum albumin
(BSA) (0. 1.0. 1.5.2. 0 and 2.5 fig). and incubated f(Jr 30 min at 37 °C. Alt er incubation.
absorbance of protein samples was measured with a spcctrophotomctc r tttc ckman Coulter
. Hrca, CA) at 562 nm and the protein concentration of experimental samplcs dctcnnin cd
from the standard curvc ttlcckman lnstrumcnts Inc. Fullerton. CAl . Atlcrstand ardizing
the protein samples. they were then mixed with 3x bromophenol blue (Sigma. St. Louis
MO).b oileda t 100 °C fllr 5minand stored at-4 5 °Cuntil theimmunoblottingp rocedure.
2.2.3 Electrophoresis and transIeI' of proteins
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was used tors eparati on of
protein sa mples on a 10% separating gel lnadel rolll: 3.44SIllII1 20.I .S761ll11.5M Tris
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(hydroxymethyl)a minomethane-hydrochloride (Tris-IICI). pI18.8 . 2.025 mI30 %
acrylamidc (29 (Acrylamidc) :1 (Bisacrylamidcj ), 3 pi tctramcthylcthylcncd iaminc
el'l:ME D) (Bio Ri\D . Hercules Ci\). 75 pi 10% ammonium pcrsulfate (i\I' S) (Pharmucia
Biotech. Baic-D' Urfc QC). The protein was initially loaded onto a 4.5 'Yostacking gel:
1.720mld ll "O. 760 pI 0.5 MT ris-l lcl pI16.8.5 00 pI3 0%aerylamide. 30 fLi!O'X, SDS.
30 fLi 10% i\ I'S. and 3 u l TEMED. Tcn ul/wcll o lcac h protein samples or pre-stained
protein ladder (Benchmark company. New York NY). ranged lrom l0 to 220 kDa. was
loaded and then run in mini-protein cell eleetrophoresise hambers( Bio-Rad. lle rcules
Ci\ ) with gel running buffer (500.2 mM tris base. 38.3 mM glycine (Sigma. St. Louis
MO).a nd7 0 mMS DS)a l I00 V Ilx 2hr ;.F oliowing electrophoresis.the protein samples
were transferred from gels to nitrocellulose membranes (13io-Ri\D . I lcrcul cs Ci\) in
tra nsfer buffer (20% methanol (i\C I'. Montreal QC). 39.82 mM glycine. 47.9 mM tris
base. 1.28mM SDS)l lx I h aliOOV .
2.2.4 lmmunoblotting
Membranes were blocked with 5% skim milk in iris-buffered saline with tween
(20mM tris and 137mM sodium chloride I'l l 7.3 containing O.I 'X, tween 20 er BST)
(Sigma.St. LouisM O) for I h. and then inc ubated with primary antibodies including:
anti-phospho-ERK (p-ERK) ( I : I0(0 ) (Cell Signalling Technology. Danvcrs Mi\: Cata log
number: 9 10I ) and anti-total-ERK (l-ERK) ( I:3( 00) (Santa Cruz Biotech. Santa Cruz
Ci\ : Catalog number: SC(4) overnight at4 °C. The next day they were washed 3 times
lo r 5 min wilh TBST. and incubated with goat anti-rabbit IgCj- horseradish peroxidase
(I: 50( 0) (Santa Cruz Biotech. Santa Cruz Ci\ : Catalog number: K04( 8) which was used
38
as thcs cconuary antibouy. Foliowing incubation withs ccondary antibody. mcmbrancs
were washed 3 times for 5 min with TBST. Bands were visualized on Fuji medical X-ray
fi lm (Fujili lm, Tokyo Japan) using AFI' imaging deve loper (AF!' Imaging Corp.
Elmsford NY) fo llowing incubation oft he membranes with millipore chcmilumincsccnt
detection kit (Millipore. Billerica MA). The band images were scanned using an cpson
perfec t ion 3 170 photo scanner (Epson, Tok yo Japan) to get ihc imagc in digital lormat Ior
subsequent densitometry analysis.
2. 3. IU -PCR
2.3. 1 RNA Extraction
RNA was extracted with TRlzol (Invitrogen. Burlington ON) according to the
manufacturcrs instruction. RNA extraction consists o r five procedures: homogenization.
separation. precipitation. R A wash. and re-dissolving the R A. At the homogenization
stcp. fissue samples with about 50 mg we ight were homogenized in l ml o fTl clzo !
applying u glass-Tcflon homogenizer. At the separation phase homogenized samples were
incubatcu lor5 min at room temperature, and then 0.2ml ofchloroform (Sigma. Si.L ou is
i\ IO) \\'as auucu to samplcs. Tubcs \\'crcs hakcn vigorously by hand tor 15 scc and
incubatcd atroom tcmpcraturc liJr3 min. Ncxl. samplcs wcrc ccntrifllgcu at l2000:\g for
15m in at4 °C.Aficr ccntrifilgc. thcaq ucous phasc. which conta ined RNA was separated
and placed in ncwtu bcs. und rhc organic phase was kept torfutu re DNA and protein
extraction.To precipitate RNA from uqucous pbusc. Do ml isopropano l (Sigma.St.Louis
MO)\\'a s auucutocach tubc. anu thcnt hc mi.'(turc \\'as incubatcua troo m temperature lor
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10 min. A fter incubation. samples were centrifuged at 12000 xg I(Jr 10 min at 4 °C.;\( the
washing level, supernatant was removed. and I ml ethanoI 7S% (Sigma. St.L ouis MO)
was added to each pallet, The mixture was then vortcxcd and ccntrifugcd at 7S00xg I(Jr S
min at 4 0C. ;\( the re-dissolving step. samples were air dried aftercentr if uge I(Jr 10 min.
pallet was then dissolved at RNAase-li-cC'water. I(Jllowed by incubating the mixture I(Jr
IOmi n at60 0C.The quantitya nd qualit;' of sampleswe remeasured based on 260/2S0
nmratiosb y Nanodrop 1000 speelrophotometer (Thermo Scientilie. Waltham MA).
2. 3.2 eDNA Synthesis
Complementary DNA (cDNA) was synthesized using Rcvert AidP ' II Minus lirSl
strand cDNA synthesis kit (Fcrmcnias. Burlington ON). The RT mixture included:
RcvcrtAid' " II Minus I'vI-MuLV reverse transcriprasc. SX reaction buffer, Ribolock
RNase inhibitor. 10 mM dNTP mix. random hcxamer primer. and SOO ng RNA diluted in
a total volumc ofo ul Dicthylpyrocarbonatc-trcutcd water. Samples were incubated I(Jr S
mina t 2S 0C foll owcd by ritl min ut-l L '" .'. lh c rcaction was terminated by heating at 70
°C forS min.
2.3.3 Standard PCR
The expression levels of Gapdh . U /JfJ2. Rig- ! and SIII12 mRNA were measured
fo ll owi ng limited PCR amplilicalionu sir g gene-specilic oligonucleotide primers
described in (Tablc L l j.Thc PCR reaction mixture included: 2 ul lUX buffer, I pi
MgCI2.
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Tahle2 .1 Gcnc spccific primcrscq ucnccs
Ge ne Primer forward Prim er reverse size
hn
CaJl/1I S'-( i(;( i l( i( i ACiC CAA M' ( ; ( ;U r c, \ -,1' S'-( ;( ;A (i(iT(iC rCOTT( ;,\A ( ;TC( ;CA-3' 532
cua S'- A(; ( ; IT AACCiCiAAAACC(,(i l('A·}' S'- CACACiTCCi( '( ;( iCT( 'ATTAAACi-}' 106
nu-t 5'- ( ,CiC,\ ( ii\ ('i\ AAC,ACi( ;;\ CiC,i\ Cii\ ·3' 5'-( '( i( iACATCCiHi(;AACi!\ACi(i-3' 150
Stat2 S'-( iTC TTC ACi!\ ( ,(,CCC!\TC!\ (; /\- } ' S-ClC i CCT TCC I(;( ;!\ U r CTC!\C-}' 507
4 1
(Fcrmcmas. Burlington ON ). 0.2 fti lO mM dcoxynuclcotidc triphosphate mix (dNTI').
0.2ftl Taq polymerase (lnvitrogen. Burlington ON) .0.5 ftlo f IOmM forwa rd primer.
0.5 ul o f 10 mM reverse primer (Integrated DNA Technologies. Co ralville IA) and 14.6
ul distillcd water. The I'CR react ion was carried out as foll ows: denaturation at 94 °C lor
I min.annealing at 63.5 °C 11.11'I min. extension at n oc 11.)1'Im in 11.11'32 cycles 11.11'
GhIJ2. Rig-f . and Stat2. The annealing temperature was set at 63 °C 11.11'Gatidh and
proceeded foro nlyZ') cycles o f amplilication. The Iinal extension was carried outat 72
°C lo r 10 mi n lorall the reactions.
2.3.4 Elcctrophoresisof l'C R products
Five ul of the I'CR products mixed with 0.5 ftl of loading butler as well as 3 ul o f
100bp ladder (Fermentas. BurlingtonO N)we re run on I'Vo Agarose gel ( lnvitrogen.
13urlington ON) containing Ethidium Bromide (Invitrogen. Burlington ON) placed on a
hor izontal gel transfer apparatus 11.11' 30 min. The gel transfcr appuratus was lillcd with l x
Trisa celate(50x stock/ml:2 42g tris bas': .5 7. l ml glociala cct ic acid. 100m 11'11.XO.5 m
ethylene diarn inc tetra acetic acid ). The PCR products were observed under UV light
using a gel logic 200 imaging system (E astma n Kodak Company. New York NY).
2../ f)ENSIT(}AII~TR Y ANALYSIS
Densitometry analysis on scanned protein fi lms and l. rhidium stained gels was
per form cd with lm ngc J sofh varc (NlI l. llc thcsda. Maryland. USA.
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hltp://imagej.nih.gov/ijl) . Protein bands were normalized to t-ERK and RT-PCR bands
were normalized to Gapdl».
2.5 STA TIS TICA L ANA LYSIS
Statistical analysis of the protein and RT-PCR densitometry ratios was performed
us ing One-way Analysis ofVariance (ANaYA) by Gra ph l'ad Prism Versi on 4
(Graphl'ad Software. La Jolla Cali fornia USA).
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Cha pte r 3: Result s
3./ . /:'FF/CIC TOF SL317 TRE·/7~\I/:W7' ON /N/IIIJITION OF Rl/.I'/Rl/flMEK /'ATI/W·Il'
/N V!r'O
The lirst step of the experiment al strategy was to determine whether the MEK
inhibitor SU27 can inhibit the activity of the Ras/Rafi'MEK pathway ill vivo. Western
blot analysis was performed to examine tile activation slateo fE RK kinase. the
downstream target of MEK. and this was represented by the phosphorylation status of
I ~ R K (p-E RK). p-ERK was examined in protein lysatcs prepared from the lungs of three
mice injected intrapcritoneally with DM ~,O or SU27 in DMSO ( 100 rug/kg I3W). 1\
specific antibody against p-ERK was used to assess the phosphorylation state. asan
indicator for the efficacy of the SU27 treatment. Intraperitoneal injection of SU27
reduced the relative ratio of phosphorylated to t-ERK in the lungs (Figure 3. 1 and Figure
3.2). The same dose and site ofd rug administration was used torsub sequent
experiments.
3.1. EFFEC/ :', OF PII l'SIOU)Ci/CAL u:'vn ,sOF AC7'1/1J:' RII.I'IRl!/!J/ EK PATI/ W / l'
ON /:'XPR/:'SSION 1.1:'11/:'1..\' OF MOIl Ci/:'NES IN 7'IIE IJR/I/ N. IN7'ESTIN/:'. AND u it«,
If the physiological activation oft he Ras/Rafi'MEK pathway suppresses the
expression of the MDII genes. inhibition of Ras/Rali'MEK would be expected to increase
their expression.
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p-E RK
Figun' 3.1 Wc stCJ"II blot anal ysis of p- ERK in the lun g Mice wer e injected
intrap cri tonca lly wit h 80 ~I of' DMSO (contro l) or SL3 27 ( 100 mg/K g ) At 8 hrs alter
injcc tion, protein sa mples were prepar ed from the lungs lor western blot ana lys is Th e
membrane s were blot ted with antibodies again st p-E RK . and t-E RK. Eac h lane number
rcpr cscn tsan ind ivid ual mou sc pcr trca tlllc nt
~ 2.5
~ 2.0
] 1.5
.a:;
~ 1.0
.~ 0.5
(ij
c.: O.O..L....----.------
mouse 1
mouse 2
mouse 3
Control 51327
Figlll ·c 3.2 Den sit ometry a na lysis of II-ERK in the lun g. Protein samples were prepared
from the lungs of mice intr aper iton eally injected with 80 p I of DMSO (co ntro l) or SU27
(100 mgl Kg) Followin g weste rn blottin g, densitom et ry of the band s W1L~ measur ed wi th
Nll i lmage J. Th e band density ofp-ERK was norma lized to that oft-ERK and plott ed
per mou se. Ho rizontal lines rep resent the mean density ± S EM
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To examine this hypothesis. Balblc female mice were treated with DMSO (control. n=5).
100 mg/kg SL327 (n=5). 1000 U/mousc IFN-u (n=5). or the combination of lFN-ul
SL327 (n=5). RNA was extracted from the brain. lung. and intestine at S hrs post
injection and subjected to semi-quantitative RT-I'CR to measure the expression oft he
ivlDll genes: Ghp2. Rig-/ and S/a/2.
3.2. 1 Brain
Figure 3.3 shows thc rclarivc changcs in clcctrophorcsis banding paucrns fo rt hc
MDII genes in the brain of mice that received control DMSO injection. SL327 alone.
IFN-u alone or SL327 in combination with IFN-u. In Figure 3.4. the densitometric ratios
for Gbp] , Rig-I and S/a/2 relative to Gapdlt are plotted for individual mice across the lour
diff erent treatment groups. along with the mean expression change.
IF -u treatment induced expression of Cih/J2 in all individual mice. but the
individual mouse responses were quite variable in SL327 treatment group (Figure 3.3 A).
For example. mouse I and 2 were the only responders to SL327 treatment based on this
semi-quantitative analysis. As a group, there were no signilicant changes in Cihp2relative
expression relative to mice receiving the vehicle control in the brain (Figure 3.4A). Co-
injection of lFN-u and SU 27 induced no synergistic effec t (Figure 3.3 A. Figure 3.-t A).
The individual mouse responses were quite variable ItlrR ig-/expression in the
brain of lFN-u treatment groups (Figure 3.3 B). For example : most robust induction of
Rig-/waso bserved in mouse 3. 4. and 5. as the induction in mouse I. and 2 was not
considerable.
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Figlll'e 3.3 RT-PCR analysis of the braiu samples. RNA was extrac ted from the brai n
o f anima ls trea ted with DMSO (co nt, n=5), and 100 mg/K g SU27 (n=5 ), 1000 U/mo use
IFN-(l (n=5 ), and SU27/1 FN-a (n=5), at :3hrs after injec tion. RT-PCR analysis W,L~
perfor med lo r (; hfl2 , Rtg -I, SIal2, and ( ;apdIJ. Each number repr esent s an ind ividual
mou se per treatm ent
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Figlll'c 3A Densitometry analysis of th e RT-P CI{ result s of till' b...lin sa mples RNA
was extracted from the brai n o f anima ls trea ted wi th DM SO (con t, n=5), and 100 mg/ Kg
SU27 (n =5), 1000 lJImo usc IFN-(x (n=5), and SU27/ IFN -IX(n=5), at 8 hrs after
injection. The band intensity o f MDII genes was no rmalized to that o f (;updh and plotted
per mouse. * P'< 0.05 by one-way analysis of'Variancc (A NOVA ). Hori zont all incs
represent the mean density ± SE M
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Expression o r Rig- 1 was up-regulated in none oft he mice following SU27
administration. As a group. thcrcwcrc oilly signilicant changcs in Rig-/rclativc
expression in the IFN-atrcatmcnt group relative to mice receiving the vehicle control
(Figure 3.4 B). Co-injection o r IFN-u and SU27 induced no synergistic eff ect (Figure 3.3
B; Figure 3.4 B).
Similarly. individual mouse responses were quite variable f(JI' SI(/I] exprcssion in
the brain ofa ll trcatment groups (Figurc 3.3 C). Forexampl e: mouse I and2wcrc non-
responders to any treatment based on this RT-PCR analysis. Mouse 3. 4 and 5 showed an
up-regulation Orsl (/l] expression in the brain following IFN-n. but only in mouse 5 SI(/I]
expression was induced following SU27 treatment. As a group. there were no significant
changes in SI(/ 12 relative expression in the brain compared to mice receiving the vehicle
control (Figure 3.4 C) . Co-injection or IFN-u and SU27 induced no synergistic effect
(Figure3. 3C; Figure 3.4 C).
3.2.2 Intcstinc
Figurc3.5 shows the relative changes in electrophoresis banding pauc rns for
MDII genes in the intestine or mice that received control DMSO injection, SU27 alone,
IFN-u alone or SU27 in combination with IFN-u. In Figure 3.6. the densitometric ratios
It)rG!JIJ]. Rig-land SI(/ 12 relative to Gapdh are plotted lor individual mice across the lour
difkrc nt trcatmentgroups.along with thc l11can expression changc.
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Figlll'c 3.5 n.T-I'en.a na lyses of th e int est ine sa mples. RNA was extrac ted fro m the
intestine of anima ls treated with DM SO (co nt, n=5), and 100 rug/K g SU27 (n=5), 1000
lJImouse IFN-u (n =5), and SU 27/ IFN-u (n=5), at Si n s after injectio n RT-PCR anal ysi s
was pe rfor med f{)[ (;hfl 2, Rig-I ,SIiI/2, and Gapdh. Each numb er repr esents an individual
mo use per treatm ent
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Fi~III'c 3.6 Den sitomet ry an alysis of the RT-I)CR resul ts of the int estin e sa mples
RNA was ex tracted [rom the intestin e ol ' .uum als treated wit h DMSO (co nt, n=5). and 100
mg/K g SL327 (n=5), 1000 lf /mousc IFN-u (n =5). and SU 27/ IF -u (n=5). at S hrs afte r
injection .The band intensity o r MD II genes were normali zed to that o r Gapdh and plott ed
per mou se. * P< 0.05 by on e-way analysis of Varian ce (A NOVA) Ho rizontal lines
represe nt the mean density ± S EM.
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i\ ll mice showed an up-regulation of CihIJ2ex pression in the intestine 1()llowingI FN-ll
administration (Figure3.5 i\ ). The individual mouse responses were variable 1()r CihIJ2 in
the intestine of Sl.327 treatment groups. as despite mouse I. 2. 3. 4. and 5. mouse 3
showed no induction of this gene (Figure 3.5 A). As a group. there were only signilicant
changes in Ghp2 relative expression in IFN-l1treated group relative to mice receiving the
vehicle control (Figure 3.6 A). Co-injection of IFN-lt and SU27 induced no synergistic
elTect (Figure 3.5 A: Figure 3.6 i\)
IFN-ll treatment induced expression of Nig-I in the intestine of all individual mice.
with a more robust induction in mouse I and 2 (Figure 3.5 B). SI.327 induced no changes
in expression level of Rig-I in the intestine ofa ny individual mice (Figure 3.5 13).
Grouping the responses of ail live mice per treatmentg roup. there wasonly signilicant
changes in Nig-/re lative expression in IFN-l1treated group relative to mice receiving the
vehicle control (Figure 3.6 B). Co-injection of IFN-ll and SU27 induced no synergistic
effect (Figure 3.5 13:Figure 3.6 B).
The individual mouse responses were variable for S/II/2 expression in the intestine
ofa ll treatment groups: for example. mouse 3 did not respond to IFN-ll treatment (Figure
3.5 C). SI.327 increased expression of Sw/20 nly in intestine of mouse I and 2 (Figure
3.5 C). As a group, there wcrc onlysigni fi cunt changes in S/II /2 relative expression in
IFN-l1treated group relative to mice receiv ing the vchiclc control( Figure 3.6 C). Co-
injection of IFN-ll and SU27 induced no synergistic effect (Figure 3.5 C: Figure 3.6 C).
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3.2.3 Lung
Figurc3 .7shows thc rclativcc h' lngcs in clcctrophorcs is banding pattcrnS ll)r thc
MDII genes in the lung o r female mice that received control DMSO injection. SU 27
alone. lIO N-a alone or SL327 in combinr.tion with lIO N-fl. In Figure 3.8. the densitometric
ratios for Ghp2 . Rig-/ and SIal 2 relative to Gapdh arc pl ott ed for individual mice across
lhcl llurdilkrcnttrcatmcnt group s.alongwiththcmcancxprcssionchangc.
Thc individual mousc rcsponscs'.Vcrc variablcf(l rGhp2 cxprcss ion in the lung of
IFN-IXtrcatmcnt groups.withm ousc 3.4 . and 5 showing a relati velyrobust respon se. but
mouse I and2 wcrc non-rcspondcrs to IFN-fl trcatmcnt bascdo n thcGh/J2 proli lc(F igurc
3.7 A). All miccshowcd an up-rcgulation o U ihp2 cxprcss ion in thc intcstinc lllilowing
SU27 admini strat ion (F igure 3.7 A). As a group. there wer e no significant changes in
Cihp2rc lativccxprcssion in thc lung comparcd to micc rccciving thc vchiclcco ntrol
(Figure 3.8 A). Co- injection or IFN-(Land SU 27 induced no synergistic effect (Figure
3.7 A: Figurc3.8 A).
The indiv idual mouse responses were quite variabl e for Rig-/cxprcssion in the
lung ora ll trcatmcntg roups. ll)r cxa mplc.aso nly mousc land2 wcrc rcspondcrs to
lIO N-IX or SU27 treatment based on this RT-I'CR analysis (Figure 3.7 B). As a group.
there were no significant changes in Rig -! relative expression relative to mice receiving
the vehicle control (Figure 3.8 B). Co- injection o r lFN-1X and SU27 induced no
synergistic effect (Figure 3.7 13: li gurc Lx B).
All mi ce showed an up-rcgulation or Slal 2 cxprcssion in the lung foll owin g lIO N-IX
administration (Figurc 3.7C) . Thc individual mousc rcsponscswcrc quitc variablc llll'
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5U27 treatment group, as only mouse I and 2 were responder to this treatment (Figure
3.7C) . As a group. there were no significant changes in S/II/2relative expression relative
to mice receiving the vehicle control (Figure 3.8 C) . Co-injection o r IFN-u and SU27
induced no synergistic effect (Figure 3.7 C: Figure 3.8 C).
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Figlll"l·3. 7 HoT -p eR a na lyse s orthe lu ng sa m ples. R A was ex tracted fro m the lun g of
anima ls tr ea ted with DMSO (corn, n=5), and 100 mgl Kg SU27 (n=5), 1000 U/mo usc
IFN-Il (n=5) , an d SU27/IFN-ll (n =5), at 8 1HS after inj ect ion . RT- I'CR ana lysis was
pe rfo rme d fo r (; I>fll , Rig-I , Sla l l , and Gapdh. Eac h nu mb er rep resen ts an ind iv idual
mouse per tr eatm ent
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Figlll'C3.8 Densitomet ry anal ysis of the RT-PCR result s of the Inng sa mples . RNA
was extracted fro m the lung of anima ls treated with DMSO (cont , n=5), and 100 mglK g
SL3 27 (n=5), 1000 Ll/mouse IFN-u (n =5 ), and SL3 27/IFN-u (n=5), at 8 hrs after
inje ction. The band intensi ty of MD II genes were nor malized to that of (iafldh and plott ed
per each individual mice. * P< 0.05 by one-wa y ana lysis of Va riance (ANOVA)
Hori zont al lines repr esent the mean density ± S EM
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C ha pte r 4: Discussion
-/.1 AI' I' U CAT/ON OFMEK INII IBIT ORSASA STRA'I'J:'(;Y l 'U l 'IW MOn' IFN
EFFICACY
Type I IFNsh avcb ccn approvcd asa thcrapcutic agcnt for various pathological
conditions. such as: IICV. IIIlV. IIIV. IICL. CML. certain types o r 13-and T-ccll
lymp homamelanom a, renal ce ll carcinoma and MS (I. 2). Eve n though othert argeted
therapies have replaced type II FNs asth cp rimarytrcatmcnt stratcgy for some oft hese
conditions. they are still an important therapyo ption f()r IIllV.I ICV. mclanoma and MS.
eithera lone or in combination with other therapies ( 150. 151. 172. 179).LJnl()rtunatcly.
despite high expectations tor rhc thcrapcutic bcncfits ofl l-N therapy. the ratc ofrc spousc
is limited by an inherent or acquired IFN resistancephen otypc inn on-rcsponsivcp atients
( 187). Oneo r the mainco ntributors to poor thcrapeutico ulcome is deregulation and over-
aClivity or cndogenous ccllulars upprcssors o r lFNs ignalling (2 10. 2 1I . 256). Ongoing
invcstigationsa re l(lCUSsedon thc potcnti:tl to targct the endogenous cellular suppresso rs
to improve IFN rcsponsivcncss (205. 213. 214). For instance. due to promising
combination e ffects or lFN-u with an inhi hitoro fSl l!"l phosph atase-sod ium
stibogluconatc. using ill l'ilm and ill l'il'Omodcl systems. clinical trials huvc progrcsscd to
phascl f()r thc combination trcatment or mclanoma( 206).
Our laboratory has identi fied the Ras/Rali'MEK pathway as an endogenous
inhibitor ofty pe I IFN signalling ( 197. 257). Activation olt hc Ras/RafiMEK pathway
trigge rs diminished IFN-u-induccd antiviral and antitumor respon ses that arc medi ated
through global down-rcgularion ofI xvls ill ac cll model (197. 257) (Chrisian ct al
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unpublished). Conversely. inhibition of Ras/Raf/Mli}; pathway via MEK inhibitor lJOl26
ill vitro induced a profound reversal in the IFN-a respons ive ness, and synergistic up-
regulation of ISGs when co-applied with IFN-l( ( 197. 257) (Christian ct ul unpublishcd).
These observations shaped the hypothesis of my research thesis. to explore the
therapeutic value of co-application of lFN-u and a MEK inhibitor in a mouse model.
This study was a first step towards improved type I IFN therapy based on Ras/Ra li'MEK
pathway targeting.
-1.2 HFFHClS OF IFN-a AN D sun ( 'OMIJ IN.,IT/ONS ON iIID11 (lf~NI:-S HXI 'HESSf(}N
The fFN treated groups wcrc a pcsitivc control fore valuat ing thc accuracy of the
experi mental procedures. Significant induction of all tested genes by fFN-u in the
intestine. and significant induction of the Hig- / in the brain suggests that the experimental
procedures including RNA extraction. PtR, densitometry and statistical analysis were
pro pc rlypcrfo nnc d.
Western blot analysis using anti-p-ERk antibody revealed that sun
successfully inhibited Ras/Rali'MEK pathway. Even though the degree of inhibiti0 11 was
corre lated with up-rcgulation ofM l.rll genes in some individual micc. it did not have a
statistically significant effect on the overall mean of SU27 treated group compared to the
control group for none of the genes in any organs. fFN-u/SU 27 co- injection also induced
no additive or synergistic effect. These outcomes arc veryd ifferent from prior ill vitro
results. where MI:K inhibition signilicantly restored the expression of MDlf genes with
determinant roles in type I IFN signalling such as G1l112. Rig-l, and S11I12. In this research.
MEK inhibition fo ll owed by 1.5-1.75 tol d changes lor G1l112. f-1.2 fold changes for Hig-I.
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and 1-1.2 fold changes for SllI12. while the relevant ratio measure from the ill vitro studies
wcrc5 .S-9.!D fold changes 1()r GhJl2. 2.55- 2.7S 1()ld changcsl ()rR ig-l . and 3.74-6.41
fold changes 1()r SIII12.Thisd iscrcpancy »ctwccn ill vitro and ill l'im obscrvationsmi ght
bc cxpluincd bysevcra l factors including: d iff erent experimental design between thc tw 0
studics (ccllular vs animal modcl). timc and conccntration dcpcndcncc of drugs and
obscrvcd dcgrcco f variation bctwccn individual mice.
./.3 EXI' IUMI:'N7/1L IJI:'SIGN: IN VITRO VS IN VIVO
Thc ill l'imc:\ pcrimcntsc:\ plorcd in thiswo rkwc rc dcsigncdb ascdon litcraturc
reports and empiri cal data gathered from cell models forM l.K inhibition and type I IFN
signalling response in the Il irasawa lab. Thcrc wcrc scvcral mcthodological dirtcrcnccs
bctwccn thcill l'ilroand illl' im studics: I)ch angc ofm odcl of studyl i'om ccll culturct o
animal: 2) change ofm easurement strutcgy from q-I'CR to RT-I'CR: and 3) changc of
MI:K inhibitor from UO126 to SU27.
Rccognition that the oncogenic activity oft he Ras/Rali'MEK pathway dctcnu incd
ce llulart ype IIF N susccptibilit yilll'ilro. lhc logical stcp wast od ctcrmincth c
physiological application of these findings.Thi s was important bccuuscvus discusscd in
section 1.6.1.3. many viruses exploit physiological activation of Ras/Rali'MEK pathway
Iorthcirrcplication. Jnbrcd Icmalc micc thatw crc notv irally. immunologicallyo rt umor-
challcngcd wcrc choscn as a modcl to invcstigatc intlucnce of physiologieal aetivationo f
Ras/Rali'MEK pathway on type I IFN responsiveness, Animal models arc more complex
than cell culture. and results can be variable based on different conditions.
Phannucokinctics is vcrydiffcrcnt from a culture model whcrc cach eell receivesth e
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same drug dose in the medium rclarivc to cclls distributcd inti ssucs andorganso f intact
animals. In addition, drugs administrated ill vivo can be injected into di ffe rent parts oft he
animal' s body. which may produce dif f erent results. In this study. the most robust
induction of lFN-u response occurred in the intestine and a question raises here is that
whether the significant stimulation of lFN-u response in intcstinc is an inllucncc ofro utc
ofi njection?
A notherco mplexity of working with mouse model is the genetic diff erence
between various strains ofm ice, such that changing thc strain 0 lmi ce may lead to
different results. For example. in efforts for learning about RIG-llilllctions. in one study
conducted in C57BL/6 lcmalc mice, knock down of Rig-/ was lethal (42). but in another
independent study. Rig-/dclicicnt mice, obtained from intcrcrossing of C57BL/6 lCmalc
mice with ICR micc.wcrc viablc(49) . ln addition.G roblewski el a/. were exploring the
effect o lT RK signalling. applying SU 27 on some aspects ofe thanol seeking behaviour
in male DBA/ 2.1micc but they lound noc orrelation (240). Their findin gs were in contrast
with two other independent studies (25S. 259). and theydi scusscd differences in III icc
strains as one of the main reasons of the inconsistency (240). Like individuals that have
di ffe rent sensitivity to l l-Ns. d i ff crcnt suuins ofm icc might have di ffere nt sensitivity to
drugs applied in this study. \Vcr an ap roof-ol:principlc cxpcrimcnt, and this dcmandsa
sensitive and thorough design, In this regard. fi rst, it is logicaI to obtain an cstimutc of
response in normal cells. indcpcndcnt ofva riabics such as strain o tm ice and routc of
injection, and this would infonu thc ncxt round ofm ouse studies,
The expressiona l changes were detected by q-PCR ill vitro, while RT-PCR was
applied ill vivo , Since several viruses exploit physiological activation of Ras/Raf/ Ml. K
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pathwayt o spreadthei rpro geny,w ee xpeetedthat similartoit s eonstitutivel llrlll o r
activity, normal activity or this signalling pathway would havc considerable eff ects on
IFN responsiveness. Therefore. we speculated that RT-I'CR is sensitive enough to detect
those major changes. This technique was also was used by Kl arnpfc r et al . while they
were investigating the effect ofo ncogenic Ki-Ras on type IIIF N responsiveness (260).
Results or my study showed less than 2 fo ld changes ofa ll tested MDII genes, while
relevant rates from ill vitro studies were more than two fold fl 'ablc IA) . My results raise
two questions: whether inhibition or physiological activation o r Ras/Ra li MEK pathway is
adequate for significant induction or MD11genes expression, and whether RT-I'CR
methodology is sensitiveen ought od eteetthese ehanges.Th esequcstions will be tested in
rutureill l'ilro studies,a s thea nsweri svery important f(lr designing the nextro und or
mouse studies.
Another difference between the two studies was a transition from UO126 to SL327
treatment. Type or MEK inhibitor is a variable, which may have influenced the results or
mye xperiments(2 3X). l lowever, Christian ellll . lllllnd no signilicant diff erence between
the cfficacy ofS l.SZ? and LJOl26 i ll vitro (257). In addition, Schcrlc et al. and others
reported superiority ofS l.J 'Z'l ovcr Uu lZo Il)rill vivo studies (244). My results also
confirmed down-regulat ion o r p-ERK by SL327 ill vivo, Ther efore . it is not expected that
switching from LJO126 to SL327 led to inconsistency between two investigations.
-1.-1TlMI:'AND cost:DHI' HNDI :'NCY OF MI:'K INIIIIJI'/'ORS AND '/')'f ' /:· IIFN.I
Based on the literature, both MEK inhibitors and type I IFNs, similar to most
drugs,aret ime and concentration dependent (240,2 4 1,2 6 1,2 62). Accordingly,
restoration o r lFN-u response by MEK inhibition was proven within a range o ft ime
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points(0-24 hrs) anuLJOI26doses( I.25-20pM)uuringfo nner stuuie s in our laboratory
( 197,257). J\sa start for perf ormi ng an ill vivo pilot study , one time point (8 hrs) and
concentrat ion ( 100 rug/kg) based on form er prelimin ary data and maximum dose
to lcrance o f' unimals was sclccrcd.
Induction of lSGsc an occur in twophases, including: primary response which
happens within minutes ofpo st injection without need for new protein synthesis:
secondary responses which happen within hours post injection and require new protein
synthes is (85). [)ependin g ont heexperimenta l eondit ions. investigationsfoeusing on
gene expressional analysis of lSGs are usua lly cond ucted between 30minandupt048
hrs 0I' post injcction ( I3. 26 I-264). F0 nne I' ~;tudies in 0 uI' Iaboratory identilicd that the
most robust stimulatory eff ect of MEK inhibit ion on ISGs transcripti on was at 6 hrs post
stimulation (19 7. 257) (Christian ('I al. unpub lished). Since in vivo is more complex than
invitro, we anticipated that it may take longer for MEK inhibitor to effect ively inhib it
Ras/Ral/Ml .K pathway i ll vivo. thereby 8 hrs was chosen as a time point of this study.
Future ill vivo studies should be performed with testing more time points testing either
before oru ltcr 8 hrs.
Expressional analysis of type II FN signalling in normal condit ions is usually
within a concentration range of 100 ILJ- 1000 III ( 13. 264) , whil e the related range lor
sun is bctween 25 mg/kg- 100 mg/kg (240-243) . Tox ieity tests in l lirasawa laboratory
revea led a dosage limit of 100 mg/kg for su n and 1000 III for IFN-u. Therefore.
aiming to obtain the most robust induction. we fol lowed a generaI theme, which was
app lyingh ighesta lloweddosage.bulin duetionleve lswerenotashi ghasweexpeeted .
Thi s docs not mean that there isn o logic of trying lower dosages. especia lly when weare
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seeking to observing synergistic eff ect. The hypothesis ofm y thcsis was tcstcd in normal
mice: there fo re, high dose ofl lN «; may mask synergistic effect. Groblcwski (' I l/I ..
during their investigations on understanding the effect s or ERK signalling on ethanol
seeking behav iour. applied two doses orS L327. including: 30 mg/kg and 50 mg/kg (240).
They observed the reverse effect ror 50 mg/kg, but not with 30 mg/kg.Thi s suggests that
applying high dosagcs ofS l.TZ? may not bc always suitablc. Jn addition. Yi (' Il/I.
conducted dosage course experiments to evaluate potential synergistic eff ect or lFN-u
with an inhibitor ol"SllPI andS II1'2 inhibitor sodium stibogluconate (204). They
combined 1000 IU ofIlN «; with different dosages ofso dium stibogluconate ranging
from 25-200 [Ig/ml, and the most robust ~ ;ynergistic cfleet was observed in the trcuunent
or25 pg/mls odiums tibogluconate (204). J\ ltogether. rutures tudiess hould be e:\panded
with different sets ofex periments testing a range ofdos ages: I) experimenta l setting I:
usc one dosage ol"lFN mixing with different dosages ol"MEK inhibitor: 2) experimental
setting 2: usc one dosage o l"MEK inhibitor combining with different dosages oI"IFN: 3)
using data from experimental setting I and 2 and testing several dosages 01"SL327 and
IFN together. These studies will helpu sinlindi ngt hebestd osagefl lr obtainingth emost
robust induction and synergistic effect .
Iligh level ofv ariation compromises the powe rofa statistical test to lind
signilicant dilk rence. while the greater number o rs amples provides a better estimation 01"
the variation to be expected in the response (265). The results 0I this study suggested that
a high degree o r variation is to be e:\pected. based on the semi-quantitativegene
6..J
expression analysis. Therefore, a set ofl ive animals pcr trcatment islikcly an
undcrcstimatc orthcnumbcr or animalsr cquircdto comct oa firm conclusion. To avoid
Iitlsc ncgativc conclusions. thc nc:\t round or mouscs tudicsshouId be expanded with
morc micc and a statisticalrowcr calculatitln.
-I.n CONCL US/() N
Thisw asa r ilot study to contributc to thca c!vanccmcnto r r ractical stratcgics for
imr rovcmcnt ort yrcllFNthcrary. Wcinv C'stigatcdthcinllucncc orc o-adminislration or
a MEK inhibitor with IFN-ll (or the expression or ISG (MDII) genes under physiological
conditions i ll vivo, Although in the current study we did not obscrvc thc significnnt eff ect
or MEK inhibition on lFN-ll rcsr onsivcncss cithcr in the absence or presence of
exogenous IFN-ll. it remains possible that otherc ell types underdifferent conditions may
yield diff erent results.Th erefore, it is important to consider developing new animal and
ccll-bascd modc ls to dc linc src cilic mcans to imrrov c IFN-ll scnsitivity. This cxplorution
mightrcquirc ab roadcr array orm ouscm odcls. such as gcnctically cnginccrcd strainsth at
arc modc ls orc anccr. autoimmunc discascor that show cnhanccd scnsitivity to viral
inf ecti on .
-1.7 FUTUR!~' D!RI:"C'T!ONS
I. Conducting ill vitro experiments to determine the effe ct o lthc Ras/Rali'MEK
pathway on IFN-ll responsiveness in normal cell lines without constitutive Ras/Rali'MEK
activation.
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Animal studies arc vcryc hallcnging and expensive. and rcsults can be variab le
bascd on diffcrcnt paramctcrs such asroutc of injcction. gcnotypc of mousc.nu mbcr of
individuals. Invitro studics hclp tog cl anc stimationo f rclation of thcsc two signalling
pathways excluding the effects ofva riable parameters. A normal ccil iinc such as NII13T3
will be chosen asa model of study. and will be treated with a I'v1 EK inhibilor. IFN-u and a
combination of both. Protein and gene expression analysis will pcrform to scck outcomcs.
Thcsc scts ofcx pcruncnts will bcp crllJrlllcd with scvcraltim c points. conccnlrations. and
several common in vivo I'v1 EK inhibitors. In ndditioncxprcssional analysis will he
performed by applying both q-I'CR and RT-I'CR. This multistep analysis will help with
bctlcrd csigning of thc ncxtro und of mousc sludics.
2.Conducting a ncwro undo fil/ li\'()s tudics to dcvclop stratcgics t0 improve type
I IFN therapy by targcting Ras/Rafll'v1EK
These set ofex periments will be designed if significant rcsults arc obscrvcd from
two il/l' itro cxpcrimcnts. ll/l 'i\'()cxpc rim,:nlsw illbc conductcd in mousc modcls
challenged with viral inlcction.h arboring I'v1 S or canccr.Th cscm odclsw ill he treated
with I'v1 EK inhibitor. IFN-u and a combination of both. Experiments will be run with a
greater numberofi ndividuals (> 10) and testing several time points and concentrations.
The disease progression will be assessed to dcrcnninc rhc cfficacyofM l. K inhibition on
improving the type IIF N therapy outcome.
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